Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Anton, Buchner"'
Publikováno v:
Journal of Immunology Research, Vol 2016 (2016)
Lipegfilgrastim is a long-acting, once-per-cycle, glycopegylated recombinant granulocyte colony-stimulating factor (G-CSF) used to prevent neutropenia in patients receiving myelosuppressive chemotherapy. This integrated analysis examined the immunoge
Externí odkaz:
https://doaj.org/article/4b6133c8acbb4fe3a5512880425c6e6b
Autor:
Depenbusch R, Monika Engelhardt, G Illerhaus, A Salar, Hartmut Link, M Zaiss, Uwe M. Martens, Andreas Lammerich, A Köhler, Anton Buchner, S. Mahlmann, Peter Bias
Publikováno v:
Supportive Care in Cancer
Abstract Background Lipegfilgrastim has been shown to be non-inferior to pegfilgrastim for reduction of the duration of severe neutropenia (DSN) in breast cancer patients. This open-label, non-inferiority study assessed the efficacy and safety of lip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a8657188cc8b2101ff28372bdb39918
http://hdl.handle.net/10230/52526
http://hdl.handle.net/10230/52526
Autor:
Patrick Liu, Nicole Lang, Ashutosh Pathak, Ruth Pettengell, Udo Mueller, Henry C. Fung, Andreas Lammerich, Ingo Diel, Anton Buchner, Camille N. Abboud, Hartmut Link
Publikováno v:
Supportive Care in Cancer. 27:2569-2577
Recombinant granulocyte colony-stimulating factors (rG-CSFs), such as filgrastim, are administered to prevent complications in patients receiving chemotherapy. In Europe, a biosimilar to filgrastim, tevagrastim/ratiograstim/biograstim, was approved i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbdf118694944a2cc8669fb57636b6b7
https://doi.org/10.1007/s00520-018-4522-5
https://doi.org/10.1007/s00520-018-4522-5
Autor:
Jelena Roganović, Linglong Zou, Gerald Hoehn, Noah Federman, Zoryana Kizyma, Monica Desiree Dragomir, Anton Buchner, Peter Bias, Andreas Lammerich, Zipi Roth-Ben Arie
Publikováno v:
Journal of Pediatric Hematology/Oncology
Volume 41
Issue 7
Volume 41
Issue 7
This phase 2, multicenter, open-label trial investigated the safety and tolerability of tbo- filgrastim in pediatric patients receiving myelosuppressive chemotherapy. In total, 50 patients 1 month to below 16 years of age with solid tumors without bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d86bd3736089f2998fb1ce17b746e7
https://repository.medri.uniri.hr/islandora/object/medri:5082/datastream/FILE0
https://repository.medri.uniri.hr/islandora/object/medri:5082/datastream/FILE0
Publikováno v:
Bioanalysis. 10(15)
Aim: This integrated analysis examined the immunogenicity of tbo-filgrastim and its potential clinical impact in three Phase III randomized studies in patients with breast cancer, lung cancer and non-Hodgkin lymphoma receiving chemotherapy. Results:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042840bfaf9df7a3ae8970602128c738
https://pubmed.ncbi.nlm.nih.gov/30058363
https://pubmed.ncbi.nlm.nih.gov/30058363
Autor:
Michael J. Lamson, Monika Csóka, Andreas Lammerich, Zoryana Kizyma, Peter Bias, Anton Buchner, Margarita B. Belogurova, Miklós Garami
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Neutropenia is a common complication from chemotherapy, limiting optimal dosing and treatment. Lipegfilgrastim is a long-acting granulocyte colony-stimulating factor developed for the management of chemotherapy-induced neutropenia. The object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff183f006a68f33312add0ee772e63ea
https://pubmed.ncbi.nlm.nih.gov/27986986
https://pubmed.ncbi.nlm.nih.gov/27986986
Publikováno v:
Journal of Immunology Research, Vol 2016 (2016)
Journal of Immunology Research
Journal of Immunology Research
Lipegfilgrastim is a long-acting, once-per-cycle, glycopegylated recombinant granulocyte colony-stimulating factor (G-CSF) used to prevent neutropenia in patients receiving myelosuppressive chemotherapy. This integrated analysis examined the immunoge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d3cf84d571fce8989388cc9e97df726
https://doaj.org/article/4b6133c8acbb4fe3a5512880425c6e6b
https://doaj.org/article/4b6133c8acbb4fe3a5512880425c6e6b
Publikováno v:
Current Medical Research and Opinion. 28:1101-1110
To compare the efficacy and safety of epoetin theta and epoetin beta in anemic patients with chronic kidney disease (CKD) not yet receiving dialysis and previously on stable maintenance therapy with epoetin beta.In this multicenter, randomized, contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f410421c72563b2fddac9612089acc94
https://doi.org/10.1185/03007995.2012.688736
https://doi.org/10.1185/03007995.2012.688736
Publikováno v:
Archives of Drug Information. 4:33-41
Introduction. Recombinant human erythropoietin (r-HuEPO) is used to treat symptomatic anaemia due to chemotherapy. A new r-HuEPO, Epoetin theta (Eporatio®), was investigated and compared to placebo in a randomised, double-blind clinical trial in adu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e7db418e3506f39e58e3fbc2c0f0215
https://doi.org/10.1111/j.1753-5174.2011.00035.x
https://doi.org/10.1111/j.1753-5174.2011.00035.x
Autor:
Depenbusch R, Uwe M. Martens, M Zaiss, Hartmut Link, Mahlmann S, A. Lammerich, A Salar, Monika Engelhardt, A Köhler, Anton Buchner, Peter Bias, G Illerhaus
Publikováno v:
Annals of Oncology. 29:viii607
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7873f47c7f3ecac1b090dbf78c63c59a
https://doi.org/10.1093/annonc/mdy300.013
https://doi.org/10.1093/annonc/mdy300.013